Nanoparticles as blood-brain barrier permeable cns targeted drug delivery systems

Topics in Medicinal Chemistry

Volumn 10, Issue , 2014, Pages 71-90

  Grabrucker, Andreas M ^a   Chhabra, Resham ^a   Belletti, Daniela ^b   Forni, Flavio ^b   Vandelli, Maria Angela ^b   Ruozi, Barbara ^b   Tosi, Giovanni ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Blood brain barrier; Central nervous system; Nanomedicine; Nanoparticles

Indexed keywords

ANTICONVULSIVE AGENT; CISPLATIN; CYCLOSPORIN A; LEUKOTRIENE C4; LIPOSOME; MACROGOL; METHOXYPOLY(ETHYLENE GLYCOL); NANOCARRIER; NANOPARTICLE; PENTETRAZOLE; POLY(N BUTYLCYANOACRYLATE); POLYGLACTIN; POLYMER; PRODRUG; SOLID LIPID NANOPARTICLE; TRANQUILIZER; UNCLASSIFIED DRUG; VINCA ALKALOID; ZIDOVUDINE; ZINC OXIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CHEMICAL MODIFICATION; CHOROID PLEXUS; CIRCUMVENTRICULAR ORGAN; DEGENERATIVE DISEASE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; EXTRACELLULAR TRAP; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; MEMBRANE PERMEABILITY; NANOMEDICINE; NONHUMAN; OMMAYA RESERVOIR; PHAGOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 84921509960     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2013_22     Document Type: Article

References (97)

1. Pardridge WM (2003) Blood brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90-105
2. Burke M, Langer R, Brim H (1999) Central nervous system: drug delivery to treat. Wiley, New York
3. Ambikanandan M, Ganesh S, Aliasgar S (2003) Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 6(2):252-273
4. Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR (1988) Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 245(3):816-822
5. Begley DJ, Sqiires LK, Zlokovic BV et al (1990) Permeability of the blood-brain barrier to the immunosuppresive cyclic peptide cyclosporin A. J Neurochem 55:1222-1230
6. Tsuji A, Tamai I (1997) Blood-brain barrier function of P-glycoprotein. Adv Drug Del Rev 25 (2):287-298
7. Cordon-Cardo C, O’Brien JP, Casals D et al (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698
8. Borst P, Evers R, Kool M et al (2000) A family of drug transporters: the multidrug resistanceassociated proteins. J Natl Cancer Inst 92:1295-1302
9. Sun H, Dai H, Shaik N et al (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105
10. Saito Y, Wright EM (1983) Bicarbonate transport across the frog choroid plexus and its control by cyclic nucleotides. J Physiol 336:635-648
11. Yarchoan R, Broder S (1987) Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. N Engl J Med 316:557-564
12. Dykstra KH, Arya A, Arriola DM et al (1993) Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharmacol Exp Ther 267:1227-1236
13. Mak M, Fung L, Strasser JF et al (1995) Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol 1995(26):91-102
14. Oldendorf WH (1972) Cerebrospinal fluid formation and circulation. Prog Nuc Med 1:336-358
15. Davson H (1969) The cerebrospinal fluid. Handbook Neurochem 2:23-48
16. Lorenzo AV, Hedley-Whyte ET, Eisenberg JM et al (1975) Increased penetration of horseradish peroxidase across the blood-brain barrier induced by Metrazol seizures. Brain Res 88:136-140
17. Neuwelt EA, Dahlborg SA (1989) Blood-brain barrier disruption in the treatment of brain tumors: clinical implications. In: Neuwelt EA (ed) Implications of the blood brain barrier and its manipulation: clinical aspects, vol 2. Plenum, New York, pp 195-262
18. Chio CC, Baba T, Black KL (1992) Selective blood-tumor pro-barrier disruption by leukotrienes. J Neurosurg 77:407-410
19. Bodor N, Buchwald P (1997) Drug targeting via retrometabolic approaches. Pharmacol Ther 76:1-27
20. Somogyi G, Nishitani S, Nomi D et al (1998) Targeted drug delivery to the brain via phosphonate derivatives. I: design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int J Pharm 166:15-26
21. Bahadur S, Pathak K (2012) Physicochemical and physiological considerations for efficient nose-to-brain targeting. Exp Opin Drug Del 9(1):19-31
22. Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47(1):49-54
23. Harbaugh RE, Saunders RL, Reeder RF (1988) Use of implantable pumps for central nervous system drug infu-sions to treat neurological disease. Neurosurgery 23(6):693-698
24. Bartneck M, Keul HA, Zwadlo-Klarwasser G et al (2010) Phagocytosis independent extracellular nanoparticles clearance by human immune cells. Nano Lett 10:59-63
25. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Rel 132:171-183
26. Chonn A, Cullis PR, Devine DV (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146:234-4241
27. Bertrand N, Leroux JC (2012) The journey of a drug-carrier in the body: an anatomophysiological perspective. J Control Rel 161(2):152-163
28. Tosi G, Costantino L, Ruozi B et al (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Exp Opin Drug Del 5:155-174
29. Shi N, Pardridge WM (2000) Noninvasive gene targeting to the brain. Prot Natl Acad Sci USA 97:7567-7572
30. Lockman PR, Mumper RJ, Khan MA et al (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28(1):1-13
31. Alyautidin RN, Gother D, Petrov V (1995) Analgesic activity of the hexapeptide dalagrin adsorbed on the surface of polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Eur J Pharm Biopharm 41:44-48
32. Kreuter J (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 4:484-488
33. Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139
34. Ji B, Maeda J, Higuchi M et al (2006) Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 78:851-855
35. Scherrmann JM, Temsamani J (2005) The use of Pep: trans vectors for the delivery of drugs into the central nervous system. Int Congr Ser 1277:199-211
36. Gabathuler R, Arthur G, Kennard M et al (2005) Development of a potential protein vector (NeuroTrans) to deliver drugs across the bloodbrain barrier. Int Congr Ser 1277:171-184
37. Chakraborty C, Sarkar B, Hsu CH et al (2009) Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol 93:285-286
38. Umezawa F, EtoY (1988) Liposomes targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Comm153:1038-1044
39. Wu D, Pardridge WM (1999) Blood-brain barrier transport of reduced folic acid. Pharm Res 16:415-419
40. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37(1):48-57
41. Panyam J, Labhasetwar V (2004) Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 1:77-84
42. Dubowchik GM, Walker MA (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm Ther 83:67-123
43. Savic R, Luo L, Eisenberg A et al (2003) Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300:615-618
44. Cengelli F, Maysinger D, Tschudi-Monnet F et al (2006) Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharm Exp Therap 318:108-116
45. Tosi G, Fano RA, Badiali L et al (2010) Peptide-engineered polylactide-co-glycolide (PLGA) nanoparticles for brain delivery of drugs: in vivo experiments and proof of concept. SfN Neurosci San Diego (USA) 1:84
46. Tosi G, Ruozi B, Belletti D (2012) Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine (Lond) 7(8):1113-1116
47. Grislain L, Couvrer P, Lenaerts V (1983) Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 15:333-345
48. Tröster SD, Kreuter J (1988) Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly(methyl methacrylate) surfaces. Int J Pharm 45:91-100
49. Silva GA (2008) Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neurosci 9(Suppl 3):S4
50. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-1569
51. Steiniger SC, Kreuter J, Khalansky AS et al (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-767
52. Alyaudtin RN, Reichel A, Lobenberg R et al (2001) Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 9:209-221
53. Schroeder U, Sommerfeld P, Ulrich S et al (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87:1305-1307
54. Zhang Y, Calon F, Zhu C et al (2003) Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 14:1-12
55. Liu G, Men P, Peggy LR et al (2006) Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406(3):189-193
56. Weiss N, Miller F, Cazaubon S et al (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788(4):842-857
57. Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13 (23-24):1099-1106
58. Beduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947-4967
59. Koo YEL, Reddy GR, Bhojani M et al (2006) Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 85:1556-1577
60. Juillerat-Jeanneret L (2006) Critical analysis of cancer therapy using nanomaterials. In: Kumar CSSR (ed) Nanomaterials for cancer therapy and diagnosis. Wiley-VCH, Weinheim, pp 199-232
61. Kreuter J, Alyautdin RN, Kharkevich DA et al (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171-174
62. Alyautdin RN, Tezikov EB, Ramge P et al (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15:67-74
63. Alyautdin RN, Petrov VE, Langer K et al (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325-328
64. Friese A, Seiller E, Quack G et al (2000) Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcya-noacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49:103-109
65. Kreuter J (1995) Nanoparticulate systems in drug delivery and targeting. J Drug Target 3:171-173
66. Aliautdin RN, Petrov VE, Ivanov AA et al (1996) Transport of the hexapeptide dalargin across the hematoencephalic barrier into the brain using polymer nanoparticles. Eksp Klin Farmakol 59:57-60
67. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81
68. Olivier JC, Fenart L, Chauvet R et al (1999) Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16:1836-1842
69. Troster SD, Muller U, Kreuter J (1990) Modification of the body distribution of poly(methyl methyl methyl-acrylate) nanoparticles by coating with surfactants. Int J Pharm 61:85-100
70. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL (2011) Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci USA 108(46):18837-18842
71. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2(1):108-119
72. Emerich DF, Tracy MA, Ward KL et al (1999) Biocompatibility of poly (DL-lactide-coglycolide) microspheres implanted into the brain. Cell Transplant 8:47-58
73. Menei P, Daniel V, Montero-Menei C et al (1993) Biodegradation and brain tissue reaction to poly(D, L-lactide-co-glycolide) microspheres. Biomaterials 14:470-478
74. Garcia-Garcia E, Andrieux K, Gil S et al (2007) Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298:274-923
75. Tosi G, Bortot B, Ruozi B et al (2013) Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr Med Chem 20(17):2212-2225
76. Li S (1999) Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 48:342-353
77. Costantino L, Gandolfi F, Tosi G et al (2005) Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Rel 108:84-96
78. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F (2007) Targeting the central nervous system: in vivo experiments with peptidederivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Rel 122:1-9
79. Vergoni AV, Tosi G, Tacchi R et al (2009) Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed Nanotechnol Biol Med 5:369-377
80. Tosi G, Fano RA, Bondioli L et al (2011) Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine 6(3):423-436
81. Grabrucker AM, Garner CC, Boeckers TM et al (2011) Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. PLoS One 6(3):e17851
82. Tosi G, Badiali L, Ruozi B et al (2012) Can Leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7(3):365-382
83. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169
84. Zhang Y, Schlachetzki F, Pardridge WM (2003) Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11-18
85. Shi N, Zhang Y, Zhu C et al (2001) Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 98:12754-12759
86. Huwyler J, Yang J, Pardridge WM (1997) Targeted delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 282:1541-1546
87. Qin J, Chen D, Hu H et al (2007) Body distribution of RGD-mediated liposome in braintargeting drug delivery. Yakugaku Zasshi 127(9):1497-1501
88. Koziara JM, Lockman PR, Allen DD et al (2003) In situ blood-brain barrier transport of nanoparticles. Pharm Res 20:1772-1778
89. Nicolas J, Mura S, Brambilla D et al (2013) Design, functionalization strategies and biomedical applications of targeted biodegradable /biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 42:1147-1235
90. Xu G, Yong KT, Roy I et al (2008) Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem 19(6):1179-1185
91. Yim YS, Choi JS, Kim GT et al (2012) A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood-brain barrier (BBB). Chem Commun (Camb) 48(1):61-63
92. Barandeh F, Nguyen PL, Kumar R et al (2012) Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS One 7(1):e29424
93. Knezevic NZ, Slowing II, Lin VS-Y (2012) Tuning the release of anticancer drugs from magnetic iron oxide/mesoporous silica core/shell nanoparticles. ChemPlusChem 77:48-55
94. Gupta PK, Hung CT (1990) Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats. J Micro-encaps 7:85-94
95. Pulfer SK, Gallo JM (1998) Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J. Drug Target 6:215-227
96. Xie Y, Wang Y, Zhang T et al (2012) Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors. J Biomed Sci 19:14
97. Grabrucker AM, Rowan M, Garner CC (2011) Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 1(1):13-23